Research at Karmanos Cancer Institute

As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are not available anywhere else. More than $60 million is invested each year into cancer research with a level of commitment and expertise that cannot be duplicated at community hospitals. 

Maximally Effective Treatment

We believe that our total focus on cancer ensures we will always be the best in developing and applying maximally effective treatment options. Our energy and resources are never diverted to other pursuits.

Learn more about research at Karmanos

    Types of Research

    A cornerstone of the Institute's cancer investigations, tracing its roots back to the establishment of the Detroit Institute for Cancer Research in 1943. Achievements include establishing the first immortal hormone dependent breast cancer cell line, MCF-7, and establishment of premalignant cell line MCF-10; and synthesis of AZT, ddC and d4T, the first FDA-approved treatments for AIDS.

    Clinical research

    Conducted through more than 800 clinical trials at the Institute, including one of the country's leading Phase I programs. Studies are institutional (designed/led by our own investigators), cooperative (with such groups as the Southwest Oncology Group), and pharmaceutical/industry trials. Achievements include establishing the international, nonsurgical standard therapy for anal and esophageal cancers and the concept of the multidisciplinary team, organ preservation and adjuvant chemotherapy.

    Population Research

    • Epidemiological research - Provides a quantitative portrait of cancer and its determinants in a defined population. Core functions are measurement of cancer incidence, morbidity, survival, and mortality. This also includes assessing of genetic predisposition, environmental and behavioral risk factors, screening practices, and the quality of care: from prevention through rehabilitation or hospice.
    • Behavioral research - Investigates whether racial and ethnic attitudes and biases, and real or perceived cultural differences among minority group patients impede effective communication and decision-making in doctor-patient interactions. 

The Latest From Karmanos Cancer Institute

News

Karmanos welcomes new VP of the Karmanos Cancer Network

The Barbara Ann Karmanos Cancer Institute has appointed Doris Ranski-Zazula, RN, MSA, as the vice president of the Karmanos Cancer Network , part ...

Read More

12 thoughtful holiday gift ideas for loved ones going through cancer treatment

If you have a loved one receiving cancer treatment during the holidays, they might spend long hours in clinics daily. Here are some great gift ide...

Read More

Stage IV lung cancer survivor, disparities cancer researcher, family physician appointed as Karmanos' new associate center director

The Barbara Ann Karmanos Cancer Institute welcomes Morhaf Al Achkar, M.D., Ph.D., MSCR, FAAFP, as the associate center director for Education. Dr....

Read More
News

IN THE NEWS: Karmanos’ new CEO on new cancer treatments, research and growth

Listen Now

IN THE NEWS: Don’t be afraid to ‘get that mammogram’

Listen Now

IN THE NEWS: 11-year breast cancer survivor shares her story, ‘I’m a medical miracle’

Listen Now